Carrier-Free Nano-Proteolysis Targeting Chimeras Enable Selective Protein Degradation and Enhance Photoimmunometabolic Therapy against Lung Adenocarcinoma - PubMed
a day ago
- #immunotherapy
- #lung adenocarcinoma
- #nanoparticles
- Carrier-free nanoparticles (MNC NPs) developed to enhance immunotherapy efficacy in lung adenocarcinoma.
- NPs integrate BRD4-targeting PROTAC, A2AR antagonist, and photosensitizer for synergistic therapy.
- Targets BRD4 and A2AR to alleviate immune resistance and reverse immunosuppression.
- Photosensitizer enables photodynamic therapy, promoting tumor ablation and immune activation.
- In vivo studies show suppression of primary, distant, and metastatic tumors.
- Nano-PROTACs combine protein degradation, immunometabolic reprogramming, and photodynamic immunotherapy.